Thursday Jul 07, 2022

Rethinking HER2-Targeted Therapy After DESTINY-04

William Gradishar, MD, talks with Robert Figlin, MD, about breast cancer research highlights from the 2022 American Society of Clinical Oncology Annual Meeting, including results from DESTINY-Breast04 and new data on CDK4/6 inhibitors from the PALOMA-2 and MAINTAIN trials.

Comment (0)

No comments yet. Be the first to say something!

HealthCentral, LLC

Version: 20241125